Acerus to Present at the 12th Annual LD Micro Main Event Investor Conference on December 10, 2019

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Dec 03, 2019 07:00 am
TORONTO -- 

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB: ASPCF) announced today that Edward Gudaitis, President and Chief Executive Officer, will present an overview of the company at the 12th Annual LD Micro Main Event investor conference at 3:40 pm Pacific Time on Tuesday December 10, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles California. The conference will be held December 9-11, 2019.

For those who wish to listen to the live webcast, please use the following link: http://wsw.com/webcast/ldmicro17/asp.to/

The webcast will be accessible live and archived on the Acerus website, www.aceruspharma.com for 90 days following the live presentation.

About the conference

The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 275 names presenting to an audience of over 1,400 attendees. In addition, there will be a variety of speakers/panelists discussing topics of interests to investors and issuers, along with coordinated evening events.

For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

About Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed partners.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Forward-Looking Information

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Robert Motz
Chief Financial Officer
Acerus Pharmaceuticals Corporation
[email protected]
(905) 817-8288

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).